These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 30507062)

  • 1. Monitoring Disease Activity in Systemic Lupus Erythematosus With Single-Molecule Array Digital Enzyme-Linked Immunosorbent Assay Quantification of Serum Interferon-α.
    Mathian A; Mouries-Martin S; Dorgham K; Devilliers H; Barnabei L; Ben Salah E; Cohen-Aubart F; Garrido Castillo L; Haroche J; Hie M; Pineton de Chambrun M; Miyara M; Sterlin D; Pha M; Lê Thi Huong D; Rieux-Laucat F; Rozenberg F; Gorochov G; Amoura Z
    Arthritis Rheumatol; 2019 May; 71(5):756-765. PubMed ID: 30507062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.
    Wang H; Li T; Chen S; Gu Y; Ye S
    Arthritis Rheumatol; 2015 Dec; 67(12):3190-200. PubMed ID: 26245802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrasensitive serum interferon-α quantification during SLE remission identifies patients at risk for relapse.
    Mathian A; Mouries-Martin S; Dorgham K; Devilliers H; Yssel H; Garrido Castillo L; Cohen-Aubart F; Haroche J; Hié M; Pineton de Chambrun M; Miyara M; Pha M; Rozenberg F; Gorochov G; Amoura Z
    Ann Rheum Dis; 2019 Dec; 78(12):1669-1676. PubMed ID: 31570366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus.
    Ho A; Magder LS; Barr SG; Petri M
    Arthritis Rheum; 2001 Oct; 44(10):2342-9. PubMed ID: 11665975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Collagen triple helix repeat containing-1: a novel biomarker associated with disease activity in Systemic lupus erythematosus.
    Wu Q; Yang Q; Sun H
    Lupus; 2018 Nov; 27(13):2076-2085. PubMed ID: 30336754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus.
    Rose T; Grützkau A; Hirseland H; Huscher D; Dähnrich C; Dzionek A; Ozimkowski T; Schlumberger W; Enghard P; Radbruch A; Riemekasten G; Burmester GR; Hiepe F; Biesen R
    Ann Rheum Dis; 2013 Oct; 72(10):1639-45. PubMed ID: 23117242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum high-mobility group box 1 is correlated with interferon-α and may predict disease activity in patients with systemic lupus erythematosus.
    Tanaka A; Ito T; Kibata K; Inagaki-Katashiba N; Amuro H; Nishizawa T; Son Y; Ozaki Y; Nomura S
    Lupus; 2019 Aug; 28(9):1120-1127. PubMed ID: 31299881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study.
    Závada J; Uher M; Svobodová R; Olejárová M; Hušáková M; Ciferská H; Hulejová H; Tomčík M; Šenolt L; Vencovský J
    Arthritis Res Ther; 2015 Nov; 17():341. PubMed ID: 26608564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of interferon alpha protein reveals differential levels and cellular sources in disease.
    Rodero MP; Decalf J; Bondet V; Hunt D; Rice GI; Werneke S; McGlasson SL; Alyanakian MA; Bader-Meunier B; Barnerias C; Bellon N; Belot A; Bodemer C; Briggs TA; Desguerre I; Frémond ML; Hully M; van den Maagdenberg AMJM; Melki I; Meyts I; Musset L; Pelzer N; Quartier P; Terwindt GM; Wardlaw J; Wiseman S; Rieux-Laucat F; Rose Y; Neven B; Hertel C; Hayday A; Albert ML; Rozenberg F; Crow YJ; Duffy D
    J Exp Med; 2017 May; 214(5):1547-1555. PubMed ID: 28420733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
    Kirou KA; Lee C; George S; Louca K; Peterson MG; Crow MK
    Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid.
    Lauwerys BR; Hachulla E; Spertini F; Lazaro E; Jorgensen C; Mariette X; Haelterman E; Grouard-Vogel G; Fanget B; Dhellin O; Vandepapelière P; Houssiau FA
    Arthritis Rheum; 2013 Feb; 65(2):447-56. PubMed ID: 23203821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus.
    Vincent FB; Kandane-Rathnayake R; Koelmeyer R; Harris J; Hoi AY; Mackay F; Morand EF
    Lupus Sci Med; 2020 Jun; 7(1):. PubMed ID: 32546562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus.
    Yao Y; Richman L; Higgs BW; Morehouse CA; de los Reyes M; Brohawn P; Zhang J; White B; Coyle AJ; Kiener PA; Jallal B
    Arthritis Rheum; 2009 Jun; 60(6):1785-96. PubMed ID: 19479852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum IFNα2 levels are associated with disease activity and outperform IFN-I gene signature in a longitudinal childhood-onset SLE cohort.
    Wahadat MJ; Qi H; van Helden-Meeuwsen CG; Huijser E; van den Berg L; van Dijk-Hummelman A; Göpfert JC; Heine A; Verkaaik M; Schreurs MWJ; Dik WA; Kamphuis S; Versnel MA
    Rheumatology (Oxford); 2023 Aug; 62(8):2872-2879. PubMed ID: 36515466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of serum interferon alpha in Egyptian patients with systemic lupus erythematosus and evaluation of its effect on disease activity: a case-control study.
    Fayed A; El Menyawi MM; Ghanema M; Shaker O; Elgohary R
    Reumatismo; 2020 Nov; 72(3):145-153. PubMed ID: 33213127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum DNase I activity in systemic lupus erythematosus: correlation with immunoserological markers, the disease activity and organ involvement.
    Skiljevic D; Jeremic I; Nikolic M; Andrejevic S; Sefik-Bukilica M; Stojimirovic B; Bonaci-Nikolic B
    Clin Chem Lab Med; 2013 May; 51(5):1083-91. PubMed ID: 23183758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Artesunate inhibits type I interferon-induced production of macrophage migration inhibitory factor in patients with systemic lupus erythematosus.
    Feng X; Chen W; Xiao L; Gu F; Huang J; Tsao BP; Sun L
    Lupus; 2017 Jan; 26(1):62-72. PubMed ID: 27230555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble TNF-R1, VEGF and other cytokines as markers of disease activity in systemic lupus erythematosus and lupus nephritis.
    Adhya Z; El Anbari M; Anwar S; Mortimer A; Marr N; Karim MY
    Lupus; 2019 May; 28(6):713-721. PubMed ID: 31046570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients.
    Niewold TB; Kelly JA; Flesch MH; Espinoza LR; Harley JB; Crow MK
    Arthritis Rheum; 2008 Aug; 58(8):2481-7. PubMed ID: 18668568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.